#USA #Lund #TFS HealthScience #Katarina Ageborg #Markus Granlund

TFS HealthScience Leadership Change

TFS HealthScience, a globally recognized Contract Research Organization (CRO), has recently announced a pivotal change in its leadership. With immediate effect, Katarina Ageborg has been appointed as the new Chairperson of the Board, while Markus Granlund has taken on the role of interim Managing Director. This transition is viewed as a crucial step towards achieving the company's mission to support global health and wellness through innovative treatments.

Katarina Ageborg brings over 25 years of invaluable experience in the life sciences field. Before this new role, she held prominent positions at AstraZeneca, where she was part of the global leadership team for several years. Her extensive background in strategic leadership, corporate governance, and patient-focused innovation is expected to be instrumental in steering the company towards a promising future. Under her guidance, TFS aims to strengthen its global footprint, deepen customer relationships, and drive sustained growth in the healthcare sector.

Markus Granlund, who joined the TFS Board in October 2024, inherits a wealth of experience from his previous role as CEO of Semcon, where he worked for 16 years. His leadership skills and operational excellence make him the perfect choice for ensuring a seamless transition. Granlund is set on maintaining TFS's commitment to high-quality service while focusing on solutions that truly improve patient lives worldwide.

“I'm excited to contribute to the growth of TFS and collaborate with our talented teams to elevate the company's industry stance,” stated Markus Granlund. “We aim to be agile, maintain operational excellence, and foster tight partnerships to meet our clients’ ever-evolving needs.”

With this new leadership team in place, TFS HealthScience plans to expand its scientific expertise and operational capabilities. The organization emphasizes innovation and strategic alliances while continuing to provide flexible, top-notch solutions that can accelerate progress in clinical research.

Markus Granlund also reiterated the importance of this leadership change, mentioning, “We are building upon our previous success to ensure TFS remains a trusted partner for biotech and pharmaceutical companies around the globe. Our commitment to delivering high-quality clinical research services and driving innovation, with a relentless focus on patients, is paramount.”

About TFS HealthScience

TFS HealthScience is a comprehensive global CRO that collaborates with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With nearly 700 experts spread across 40 countries, TFS and its strategic partners offer tailored strategic resourcing solutions and clinical development services across specialized therapeutic areas including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. The organization is dedicated to empowering partners and enriching lives by delivering adaptable solutions that combine global reach with the flexibility inherent in a mid-sized CRO.

To learn more about TFS HealthScience, visit www.tfscro.com.